Clinical Update and Treatment of Idiopathic Pulmonary Fibrosis

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Pulmonary".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 1912

Special Issue Editor


E-Mail Website1 Website2 Website3
Guest Editor
1. Center for Research and Innovation in Personalized Medicine of Respiratory Diseases, Discipline of Pneumology “Victor Babes”, University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania
2. Center of Expertise for Adult Rare Respiratory Diseases, IInd Clinic of Pulmonology, Clinical Hospital of Infectious Diseases and Pneumophthisiology “Dr. Victor Babes” Timisoara, 300310 Timisoara, Romania
Interests: interstitial lung diseases; pulmonary hypertension; pulmonary function and exercise testing; i-health and telemedicine

Special Issue Information

Dear Colleagues,

Idiopathic pulmonary fibrosis (IPF) is a challenging disease characterized by poor survival. Although the accuracy and timeliness of IPF diagnosis have improved in the last decade, and existing antifibrotic therapies have proven to significantly alleviate disease progression, many challenges and unmet needs remain in the management of the disease.

This Special Issue aims to provide a thorough overview of current knowledge and investigate future directions in the diagnosis and treatment of IPF. With a view to identifying new insights into IPF management, we are pleased to invite authors to share systematic reviews or meta-analyses, original research, pilot studies, and interesting case reports. Research areas may include (but are not limited to) the following: pathogenic pathways and mediators, diagnosis and prognostic evaluation, existing and emerging pharmacological therapies, biomarkers for guiding therapy, palliative intervention, and developments in lung transplantation.

Dr. Ovidiu Fira-Mladinescu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • interstitial lung diseases
  • progressive pulmonary fibrosis
  • clinical phenotypes
  • antifibrotic therapy
  • pulmonary rehabilitation
  • lung transplant

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

8 pages, 1244 KiB  
Case Report
Drug-Induced Thrombocytopenia Due to Nintedanib during Treatment of Idiopathic Pulmonary Fibrosis
by Igor Dumic, Antonios Charokopos, Angadabir Parmar, Christopher R. Grant, Ronin Joshua S. Cosiquien, Marilia Dagnon da Silva and Emilia Petcu
Medicina 2023, 59(5), 999; https://doi.org/10.3390/medicina59050999 - 22 May 2023
Cited by 2 | Viewed by 1631
Abstract
Nintedanib is a tyrosine kinase inhibitor that was approved for the treatment of patients with idiopathic pulmonary fibrosis in 2014. The most common side effect of Nintedanib is diarrhea, and thrombocytopenia is a rare side effect of Nintedanib. The exact mechanism is unknown, [...] Read more.
Nintedanib is a tyrosine kinase inhibitor that was approved for the treatment of patients with idiopathic pulmonary fibrosis in 2014. The most common side effect of Nintedanib is diarrhea, and thrombocytopenia is a rare side effect of Nintedanib. The exact mechanism is unknown, and the literature lacks case reports of this phenomenon. Here, we report the case of a patient who developed thrombocytopenia 12 weeks after starting treatment with Nintedanib. The patient underwent an extensive work up for infectious, hematological, autoimmune, and neoplastic diseases. The patient’s thrombocytopenia resolved following cessation of Nintedanib. This case is significant as it reports a rare side effect that might have detrimental consequences if not recognized and treated timely. Additionally, the onset of thrombocytopenia was delayed, 3 months after the initiation of Nintedanib. We also highlight the various literature regarding drug-induced thrombocytopenia and explore the necessary work-up needed to exclude other potential diagnoses. We hope to advocate for multidisciplinary teams to be aware of patients with pulmonary fibrosis on Nintedanib so that this adverse effect can be recognized promptly. Full article
(This article belongs to the Special Issue Clinical Update and Treatment of Idiopathic Pulmonary Fibrosis)
Show Figures

Figure 1

Back to TopTop